Abbott reports positive trial data for new Parkinson’s treatment

Abbott has announced positive clinical trial data from a phase III trial of levodopa-carbidopa intestinal gel (LCIG), its new treatment for advanced Parkinson's disease.

The investigational product has been evaluated in a 12-week study that aimed to establish the efficacy, safety and tolerability of continuous LCIG infusion compared with standard levodopa-carbidopa IR tablets.

It was found that Abbott's new therapy option can deliver significant improvements in "off" time – periods of poor mobility, slowness and stiffness – without any accompanying increase in troublesome dyskinesia.

This demonstrates the potential benefits LCIG can offer to late-stage Parkinson's sufferers who are affected by a reduced quality of life.

Dr Robert Lenz, divisional vice-president for global pharmaceutical research and development at Abbott, said: "Many patients at this stage are in need of additional treatment options and we hope that LCIG may soon be a viable option for some of these patients."

Earlier this month, the company received European regulatory approval for its drug Humira to be used as a treatment for ulcerative colitis.